Phase 1Completed
Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient
Evaluation of Rheumatoid Arthritis Patient Performance Using the Metoject® Prefilled Pen (Methotrexate 50 mg/mL, Prefilled Pen) for Subcutaneous Injection and Subsequent Pharmacokinetic Assessment of Drug Delivery
- Sponsor
- medac GmbH (Industry)
- Enrolment
- 105 enrolled
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Methotrexate (Metoject® prefilled pen)
- Ages
- children, adults, older adults
- Registry
- NCT01871961
Full record on ClinicalTrials.gov
From the registry
To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).
Primary outcomes
- To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).
History
Last registry update
Registered
Study completion
Primary completion
Started